Daly, A.F., Beckers, A., The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49:3 (2020), 347–355.
Tichomirowa, M.A., Barlier, A., Daly, A.F., et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165:4 (2011), 509–515.
Vierimaa, O., Georgitsi, M., Lehtonen, R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:5777 (2006), 1228–1230.
Igreja, S., Chahal, H.S., King, P., et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 31:8 (2010), 950–960.
Oriola, J., Lucas, T., Halperin, I., et al. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168:1 (2013), 9–13.
Gadelha, M.R., Kasuki, L., Korbonits, M., Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:5 (2013), 238–246.
Daly, A.F., Tichomirowa, M.A., Petrossians, P., et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:11 (2010), E373–E383.
Rostomyan, L., Daly, A.F., Petrossians, P., et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22:5 (2015), 745–757.
Joshi, K., Daly, A.F., Beckers, A., Zacharin, M., Resistant paediatric somatotropinomas due to AIP mutations: role of pegvisomant. Horm Res Paediatr 90:3 (2018), 196–202.
Bidlingmaier, M., Friedrich, N., Emeny, R.T., et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 99:5 (2014), 1712–1721.
Theodoropoulou, M., Tichomirowa, M.A., Sievers, C., et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 125:9 (2009), 2122–2126.
Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S., Rabinowitz, D., Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:8 (2005), 4465–4473.
van der Lely, A.J., Hutson, R.K., Trainer, P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:9295 (2001), 1754–1759.
Bevan, J.S., Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:3 (2005), 1856–1863.
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:5 (2002), 707–716.
Muhammad, A., Coopmans, E.C., Gatto, F., et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab 104:3 (2019), 915–924.
Hofland, L.J., van der Hoek, J., van Koetsveld, P.M., et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:4 (2004), 1577–1585.
Daly, A.F., Rostomyan, L., Betea, D., et al. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect 8:4 (2019), 367–377.
Bogner, E.M., Daly, A.F., Gulde, S., et al. miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int J Cancer 147:12 (2020), 3523–3538.
Coopmans, E.C., Schneiders, J.J., El-Sayed, N., et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol 182:6 (2020), 595–605.
Iacovazzo, D., Carlsen, E., Lugli, F., et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174:2 (2016), 241–250.
Korbonits, M., Kumar, A.V., AIP Familial isolated pituitary adenomas. Adam, M.P., Ardinger, H.H., Pagon, R.A., et al. (eds.) GeneReviews, 2012, University of Washington Updated April 16, 2020. Accessed January 27, 2021.
